Scinai Immunotherapeutics Ltd. (SCNI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
JERUSALEM BIOPARK, 2ND FLOOR JERUSALEM, 00000 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2022 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | |||
| Cash and cash equivalents | |||
| Restricted cash and investments | |||
| Receivables | |||
| Total current assets: | |||
| Noncurrent Assets | |||
| Operating lease, right-of-use asset | |||
| Property, plant and equipment | |||
| Total noncurrent assets: | |||
| TOTAL ASSETS: | |||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | |||
| Accounts payable | |||
| Debt | |||
| Other undisclosed current liabilities | |||
| Total current liabilities: | |||
| Noncurrent Liabilities | |||
| Long-term debt and lease obligation | |||
| Long-term debt, excluding current maturities | |||
| Liabilities, other than long-term debt | |||
| Operating lease, liability | |||
| Derivative instruments and hedges, liabilities | |||
| Total noncurrent liabilities: | |||
| Total liabilities: | |||
| Equity | |||
| Equity, attributable to parent | |||
| Additional paid in capital | |||
| Accumulated other comprehensive loss | |||
| Accumulated deficit | |||
| Total equity: | |||
| TOTAL LIABILITIES AND EQUITY: | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2022 | ||
|---|---|---|
| Revenues (Sublease Income) | ||
| Gross profit: | ||
| Operating expenses | ||
| Other operating expense, net (Other Expenses) | ||
| Other undisclosed operating loss | ||
| Operating loss: | ||
| Nonoperating income | ||
| Other nonoperating income | ||
| Loss from continuing operations before income taxes: | ||
| Other undisclosed income from continuing operations | ||
| Net income: | ||
| Other undisclosed net loss attributable to parent | ||
| Net loss available to common stockholders, diluted: | ||
Comprehensive Income ($ in thousands)
| 12/31/2022 | ||
|---|---|---|
| Net income: | ||
| Other comprehensive income | ||
| Comprehensive income: | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | ||
| Comprehensive loss, net of tax, attributable to parent: | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.